arrow
P

Paul Emery

University of Leeds
H指数:158
被引数:12.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-line biologic and targeted synthetic DMARDs versus methotrexate in early rheumatoid arthritis: a meta-analysis of remission outcomes

早期类风湿关节炎中一线生物制剂和靶向合成DMARDs与甲氨蝶呤的比较:缓解结局的荟萃分析

2026-09-170
OAAI
DNA hypo-methylation of the TNFA gene predicts response to MTX in RA but not in PsA

肿瘤坏死因子α基因低甲基化可预测类风湿关节炎对甲氨蝶呤的应答,但无法预测银屑病关节炎的应答

2026-08-280
PRE
Baseline interleukin-10 levels as a predictive biomarker for achieving clinical response with abatacept in disease-modifying antirheumatic drug-naive and anticitrullinated protein antibody-positive patients with early rheumatoid arthritis

基线白细胞介素-10水平作为预测阿达木单抗治疗早期类风湿关节炎患者临床反应的生物标志物(适用于疾病 modifying antirheumatic drug-naive 且抗瓜氨酸化蛋白抗体阳性的患者)

2026-02-240
PRE
Effect of a treatment strategy utilising golimumab, methotrexate and corticosteroids versus methotrexate and corticosteroids in early, untreated psoriatic arthritis (GOLMePsA): a single-centre, double-blind, parallel-group, randomised controlled trial

利用戈利木单抗、甲氨蝶呤和糖皮质激素的治疗策略与甲氨蝶呤和糖皮质激素在早期、未治疗的银屑病关节炎中的效果比较(GOLMePsA):一项单中心、双盲、平行组、随机对照试验

2025-09-030
PRE
Entheseal structural damage according to OMERACT definitions unveils distinct ultrasound phenotypes in SpA: findings from the DEUS multicentre study

根据OMERACT定义的肌腱端结构损伤揭示了SpA中不同的超声表型:DEUS多中心研究的结果

2025-08-280
OAAI
Whole-body MRI in patients with arthralgia or inflammatory arthritis after exposure to immune checkpoint inhibitors: a single-centre prospective imaging study

免疫检查点抑制剂暴露后出现关节痛或炎症性关节炎患者的全身MRI:一项单中心前瞻性影像学研究

2025-06-100
OAAI
ULTRASOUND FEATURES IN PATIENTS WITH INFLAMMATORY ARTHRITIS AND ARTHRALGIA FOLLOWING IMMUNE CHECKPOINT INHIBITOR THERAPY FOR CANCER: RESULTS OF A MULTI- CENTRE STUDY

免疫检查点抑制剂治疗癌症后,炎症性关节炎和关节痛患者的超声特征:一项多中心研究的结果

2024-06-010
PRE
Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial

Abatacept治疗类风湿关节炎高危人群 (APIPPRA): 一项随机、双盲、多中心、平行、安慰剂对照、2b期临床试验

LANCET
IF88.5
2024-03-0134
OAAI